Abstract
Ever since the development of CRISPR-Cas9 genome editing a decade ago, hopes have risen that this technology could deliver a new era of precision medicine. To date, some 200 patients have been or are currently in clinical trials for blood diseases, liver diseases, and various forms of cancer. That number is likely to grow substantially over the next few years as the first CRISPR-based therapies head to regulatory approval.
Despite this progress, there are huge challenges to overcome if the promise of CRISPR in the clinic is to be realized. They span improvements in foundational gene editing and delivery platforms to improvements in the funding, regulatory, and networking framework to expand CRISPR therapies to hundreds or thousands of rare diseases.
For our next special issue, The CRISPR Journal invites the submission of manuscripts (original research, review articles, perspectives) on all aspects of Preclinical gene editing Clinical trials Economic analysis Regulatory affairs Academic-industry patnerships Viral and nonviral gene delivery Rare diseases Advances in base and prime editing Novel gene editing tools and technologies Companion diagnostics
This exciting special issue will be published in early 2024. Manuscripts will receive prompt peer review and accepted articles will be published online (epub) ahead of print. Please refer to our
Pre-submission inquiries may be sent to The CRISPR Journal (editorial@crisprjournal.com). Deadline for submissions is
Rapid, high-quality peer review, and editorial oversight
Fast electronic submission
Maximum exposure: accessible in 170 countries worldwide
High visibility: International press and social media outreach
Open Access options available